DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Growth Opportunities in the Global Structural Heart Device Market" report to their offering.
The global structural heart device market is expected to reach an estimated $9.7 billion by 2022 and it is forecast to grow at a CAGR of 14.3% from 2017 to 2022.
Trends, opportunities and forecast in this market to 2022 by procedure, which includes repair (annuloplasty, valvuloplasty, transcatheter mitral valve repair, and other repairs) and replacement (surgical valves, mechanical heart valves, tissue heart valves, and transcatheter aortic valves), position (aorta, mitral, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)
The global structural heart device market looks promising with opportunities in public and private hospitals. The major drivers for market growth are growing demand for minimally invasive surgery, growing healthcare expenditure, and a growing geriatric population.
Emerging trends which have a direct impact on the dynamics of the structural heart device industry include rising adoption of transcatheter aortic valve replacement procedure and introduction of new hybrid tissue engineered heart valve.
Scope of the Report
Structural heart device market by procedure [$ million shipment analysis from 2011 to 2022]:
- Transcatheter Mitral Valve Repair (TMVR)
- Repair Other
- Surgical Valve
- Mechanical Heart Valve
- Tissue Heart Valve
- Transcatheter Aortic Valve Replacement (TAVR)
Structural heart device market by position [$ million shipment analysis from 2011 to 2022]:
- Abbott Laboratories
- Boston Scientific Corporation
- C. R. Bard, Inc.
- CryoLife Inc.
- Edwards Lifesciences Corporation
- JenaValve Technology Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
- LivaNova PLC
- Medtronic Public Limited Company
- St. Jude Medical, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/fwllcz/growth